Multicentric Single Arm Phase II Clinical Trial, to Evaluate Safety and Efficacy of the Combination of Olaparib and PLD for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tube Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 27 Aug 2018
At a glance
- Drugs Olaparib (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ROLANDO
- 31 Aug 2018 Biomarkers information updated
- 17 Aug 2018 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
- 17 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.